<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493220</url>
  </required_header>
  <id_info>
    <org_study_id>1838-004</org_study_id>
    <nct_id>NCT00493220</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration</brief_title>
  <acronym>INFUSE-Cftrx</acronym>
  <official_title>INcreased Flow Utilizing Subcutaneously-Enabled Ceftriaxone (INFUSE-Ceftriaxone) Study: A Phase I Study Comparing the Safety and Pharmacokinetics of Ceftriaxone Administered Subcutaneously With and Without Human Recombinant Hyaluronidase (HYLENEX Recombinant) and Intravenously in Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:

        -  to establish the safety of subcutaneous administration of ceftriaxone at different
           concentrations, with and without HYLENEX recombinant, and to determine the maximum
           tolerated concentration;

        -  and to establish the pharmacokinetic comparability of subcutaneous administration of
           ceftriaxone with HYLENEX recombinant to subcutaneous administration without HYLENEX
           recombinant and to IV administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Start of ceftriaxone administration through time of last measureable plasma ceftriaxone concentration</time_frame>
    <description>Area under the drug concentration-time curve from time zero to the time of the last measurable concentration (calculated by the linear trapezoidal method)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>from the start of ceftriaxone administration to infinity</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity, calculated as AUC0-t + Ct/kel (Ct = time of last measurable concentration; kel = terminal elimination rate constant)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>at the time of the highest measured plasma ceftriaxone concentration</time_frame>
    <description>Maximum measured plasma ceftriaxone concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>from start of ceftriaxone administration until time of maximum measured plasma ceftriaxone concentration</time_frame>
    <description>Time to maximum measured plasma ceftriaxone concentration</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HYLENEX SC, Placebo SC, IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HYLENEX SC, IV, Placebo SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC, HYLENEX SC, IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC, IV, HYLENEX SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV, HYLENEX SC, Placebo SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV, Placebo SC, HYLENEX SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC HYLENEX and Ceftriaxone</intervention_name>
    <description>single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)</description>
    <arm_group_label>HYLENEX SC, Placebo SC, IV</arm_group_label>
    <arm_group_label>HYLENEX SC, IV, Placebo SC</arm_group_label>
    <arm_group_label>Placebo SC, HYLENEX SC, IV</arm_group_label>
    <arm_group_label>Placebo SC, IV, HYLENEX SC</arm_group_label>
    <arm_group_label>IV, HYLENEX SC, Placebo SC</arm_group_label>
    <arm_group_label>IV, Placebo SC, HYLENEX SC</arm_group_label>
    <other_name>HYLENEX recombinant</other_name>
    <other_name>hyaluronoglucosaminidase</other_name>
    <other_name>hyaluronidase</other_name>
    <other_name>rHuPH20</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC Placebo and Ceftriaxone</intervention_name>
    <description>single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)</description>
    <arm_group_label>HYLENEX SC, Placebo SC, IV</arm_group_label>
    <arm_group_label>HYLENEX SC, IV, Placebo SC</arm_group_label>
    <arm_group_label>Placebo SC, HYLENEX SC, IV</arm_group_label>
    <arm_group_label>Placebo SC, IV, HYLENEX SC</arm_group_label>
    <arm_group_label>IV, HYLENEX SC, Placebo SC</arm_group_label>
    <arm_group_label>IV, Placebo SC, HYLENEX SC</arm_group_label>
    <other_name>saline</other_name>
    <other_name>normal saline</other_name>
    <other_name>0.9% sodium chloride injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Ceftriaxone</intervention_name>
    <description>single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)</description>
    <arm_group_label>HYLENEX SC, Placebo SC, IV</arm_group_label>
    <arm_group_label>HYLENEX SC, IV, Placebo SC</arm_group_label>
    <arm_group_label>Placebo SC, HYLENEX SC, IV</arm_group_label>
    <arm_group_label>Placebo SC, IV, HYLENEX SC</arm_group_label>
    <arm_group_label>IV, HYLENEX SC, Placebo SC</arm_group_label>
    <arm_group_label>IV, Placebo SC, HYLENEX SC</arm_group_label>
    <other_name>ceftriaxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18-65 years of age

          -  If female: non-lactating; non-pregnant; and incapable of becoming pregnant, or taking
             specific precautions to avoid becoming pregnant before and during study

          -  Normal clinical laboratory parameters

          -  Adequate venous access in both upper extremities

          -  Agreeing to refrain from smoking and from ingesting any alcohol or caffeine-containing
             products before and during the study

          -  Good health based on medical history, physical examination and laboratory tests

          -  Non-smoking; or smoking less than 10 cigarettes per day and willing to refrain from
             use of nicotine products before and during study

        Exclusion Criteria:

          -  Received a cephalosporin within the 21 days prior to study or anticipated to receive
             non-study cephalosporin during study

          -  Pregnant or breast-feeding.

          -  Previously exposed to a hyaluronidase drug product

          -  Medical condition presenting unacceptable safety risk or likely to prevent completion
             of study

          -  Known hypersensitivity to hyaluronidase or any other ingredient in HYLENEX recombinant

          -  Contraindication to ceftriaxone, including known allergy to beta-lactam antibiotics

          -  Local condition precluding subcutaneous injection or injection site evaluation

          -  History of gastrointestinal disease (in particular colitis)

          -  Consumption of caffeine- or other methylxanthine-containing beverage within 24 hours
             before and/or during the PK sampling period

          -  Participation in study of any investigational drug or device within 30 days before
             this study

          -  Serum hemoglobin &lt;12 g/dL.

          -  Blood donation or significant loss of blood within 56 days, or plasma donation within
             7 days, prior to study

          -  Medical history/condition, screening physical examination finding or clinical
             laboratory result precluding safe participation in study, or which might adversely
             effect interpretation of study results

          -  History of drug or alcohol abuse within 2 years prior to study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George E Harb, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010 Feb;26(2):279-88. doi: 10.1185/03007990903432900.</citation>
    <PMID>19947907</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2007</study_first_posted>
  <results_first_submitted>September 12, 2011</results_first_submitted>
  <results_first_submitted_qc>October 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2011</results_first_posted>
  <last_update_submitted>October 24, 2011</last_update_submitted>
  <last_update_submitted_qc>October 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Geroge E. Harb, MD</name_title>
    <organization>Baxter Healthcare Corporation</organization>
  </responsible_party>
  <keyword>ceftriaxone</keyword>
  <keyword>cephalosporins</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>hyaluronoglucosaminidase</keyword>
  <keyword>hyaluronidase</keyword>
  <keyword>hyaluronan</keyword>
  <keyword>rHuPH20</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy volunteers recruited via subject-initiated telephone or internet contacts or visits to Phase I unit. Those considered potentially eligible were, after obtaining consent, screened in detail to determine eligibility against protocol eligibility criteria.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HYLENEX SC, Placebo SC, IV</title>
          <description>subcutaneous HYLENEX and ceftriaxone as first intervention, subcutaneous placebo and ceftriaxone as second intervention, intravenous ceftriaxone as third intervention</description>
        </group>
        <group group_id="P2">
          <title>HYLENEX SC, IV, Placebo SC</title>
          <description>subcutaneous HYLENEX and ceftriaxone as first intervention, intravenous ceftriaxone as second intervention, subcutaneous placebo and ceftriaxone as third intervention</description>
        </group>
        <group group_id="P3">
          <title>Placebo SC, HYLENEX SC, IV</title>
          <description>subcutaneous placebo and ceftriaxone as first intervention, subcutaneous HYLENEX and ceftriaxone as second intervention, intravenous ceftriaxone as third intervention</description>
        </group>
        <group group_id="P4">
          <title>Placebo SC, IV, HYLENEX SC</title>
          <description>subcutaneous placebo and ceftriaxone as first intervention, intravenous ceftriaxone as second intervention, subcutaneous HYLENEX and ceftriaxone as third intervention</description>
        </group>
        <group group_id="P5">
          <title>IV, HYLENEX SC, Placebo SC</title>
          <description>intravenous ceftriaxone as first intervention, subcutaneous HYLENEX and ceftriaxone as second intervention, subcutaneous placebo and ceftriaxone as third intervention</description>
        </group>
        <group group_id="P6">
          <title>IV, Placebo SC, HYLENEX SC</title>
          <description>intravenous ceftriaxone as first intervention, subcutaneous placebo and ceftriaxone as second intervention, subcutaneous HYLENEX and ceftriaxone as third intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First 7-Day Washout &amp; Safety Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second 7-Day Washout &amp; Safety Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Final 7-Day Safety Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HYLENEX SC, Placebo SC, IV</title>
          <description>subcutaneous HYLENEX and ceftriaxone as first intervention, subcutaneous placebo and ceftriaxone as second intervention, intravenous ceftriaxone as third intervention</description>
        </group>
        <group group_id="B2">
          <title>HYLENEX SC, IV, Placebo SC</title>
          <description>subcutaneous HYLENEX and ceftriaxone as first intervention, intravenous ceftriaxone as second intervention, subcutaneous placebo and ceftriaxone as third intervention</description>
        </group>
        <group group_id="B3">
          <title>Placebo SC, HYLENEX SC, IV</title>
          <description>subcutaneous placebo and ceftriaxone as first intervention, subcutaneous HYLENEX and ceftriaxone as second intervention, intravenous ceftriaxone as third intervention</description>
        </group>
        <group group_id="B4">
          <title>Placebo SC, IV, HYLENEX SC</title>
          <description>subcutaneous placebo and ceftriaxone as first intervention, intravenous ceftriaxone as second intervention, subcutaneous HYLENEX and ceftriaxone as third intervention</description>
        </group>
        <group group_id="B5">
          <title>IV, HYLENEX SC, Placebo SC</title>
          <description>intravenous ceftriaxone as first intervention, subcutaneous HYLENEX and ceftriaxone as second intervention, subcutaneous placebo and ceftriaxone as third intervention</description>
        </group>
        <group group_id="B6">
          <title>IV, Placebo SC, HYLENEX SC</title>
          <description>intravenous ceftriaxone as first intervention, subcutaneous placebo and ceftriaxone as second intervention, subcutaneous HYLENEX and ceftriaxone as third intervention</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="10.6"/>
                    <measurement group_id="B2" value="37.6" spread="4.0"/>
                    <measurement group_id="B3" value="34.2" spread="11.5"/>
                    <measurement group_id="B4" value="34.8" spread="17.5"/>
                    <measurement group_id="B5" value="34.8" spread="11.0"/>
                    <measurement group_id="B6" value="33.2" spread="8.0"/>
                    <measurement group_id="B7" value="34.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum measured plasma ceftriaxone concentration</description>
        <time_frame>at the time of the highest measured plasma ceftriaxone concentration</time_frame>
        <population>Per protocol (excludes one participant that did not receive intravenous ceftriaxone intervention)</population>
        <group_list>
          <group group_id="O1">
            <title>HYLENEX SC</title>
            <description>All per-protocol participants administered subcutaneous hylenex and ceftriaxone</description>
          </group>
          <group group_id="O2">
            <title>Placebo SC</title>
            <description>All per-protocol participants administered subcutaneous placebo and ceftriaxone</description>
          </group>
          <group group_id="O3">
            <title>Intravenous</title>
            <description>All per-protocol participants administered intravenous ceftriaxone</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum measured plasma ceftriaxone concentration</description>
          <population>Per protocol (excludes one participant that did not receive intravenous ceftriaxone intervention)</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" spread="15.1"/>
                    <measurement group_id="O2" value="82.2" spread="13.5"/>
                    <measurement group_id="O3" value="150" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence = 90% confidence interval of least squares mean (LSM) within 80%-125%</non_inferiority_desc>
            <param_type>LSM ratio (natural log-transformed)</param_type>
            <param_value>111.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>108.57</ci_lower_limit>
            <ci_upper_limit>115.12</ci_upper_limit>
            <estimate_desc>HYLENEX SC/Placebo SC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence = 90% confidence interval of least squares mean (LSM) within 80%-125%</non_inferiority_desc>
            <param_type>LSM ratio (natural log-transformed)</param_type>
            <param_value>60.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.06</ci_lower_limit>
            <ci_upper_limit>62.62</ci_upper_limit>
            <estimate_desc>HYLENEX SC/Intravenous</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence = 90% confidence interval of least squares mean (LSM) within 80%-125%</non_inferiority_desc>
            <param_type>LSM ratio (%; ln-transformed)</param_type>
            <param_value>54.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>52.82</ci_lower_limit>
            <ci_upper_limit>56.01</ci_upper_limit>
            <estimate_desc>Placebo SC/Intravenous</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time to maximum measured plasma ceftriaxone concentration</description>
        <time_frame>from start of ceftriaxone administration until time of maximum measured plasma ceftriaxone concentration</time_frame>
        <population>Per protocol (excludes one participant that did not receive intravenous ceftriaxone intervention)</population>
        <group_list>
          <group group_id="O1">
            <title>HYLENEX SC</title>
            <description>All per-protocol participants administered subcutaneous HYLENEX and ceftriaxone</description>
          </group>
          <group group_id="O2">
            <title>Placebo SC</title>
            <description>All per-protocol participants administered subcutaneous placebo and ceftriaxone</description>
          </group>
          <group group_id="O3">
            <title>Intravenous</title>
            <description>All per-protocol participant administered intravenous ceftriaxone</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to maximum measured plasma ceftriaxone concentration</description>
          <population>Per protocol (excludes one participant that did not receive intravenous ceftriaxone intervention)</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.02" upper_limit="3.01"/>
                    <measurement group_id="O2" value="3.02" lower_limit="1.52" upper_limit="4.04"/>
                    <measurement group_id="O3" value="0.502" lower_limit="0.501" upper_limit="0.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon signed-rank test</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>-0.75</ci_upper_limit>
            <estimate_desc>HYLENEX SC minus Placebo SC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon signed-rank test</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>Placebo SC minus Intravenous</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon signed-rank test</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>2.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.26</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
            <estimate_desc>Placebo SC minus Intravenous</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t</title>
        <description>Area under the drug concentration-time curve from time zero to the time of the last measurable concentration (calculated by the linear trapezoidal method)</description>
        <time_frame>Start of ceftriaxone administration through time of last measureable plasma ceftriaxone concentration</time_frame>
        <population>Per protocol (excludes one participant that did not receive intravenous ceftriaxone intervention)</population>
        <group_list>
          <group group_id="O1">
            <title>HYLENEX SC</title>
            <description>All per-protocol participants administered subcutaneous HYLENEX and ceftriaxone</description>
          </group>
          <group group_id="O2">
            <title>Placebo SC</title>
            <description>All per-protocol participants administered subcutaneous placebo and ceftriaxone</description>
          </group>
          <group group_id="O3">
            <title>Intravenous</title>
            <description>All per-protocol participants administered intravenous ceftriaxone</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t</title>
          <description>Area under the drug concentration-time curve from time zero to the time of the last measurable concentration (calculated by the linear trapezoidal method)</description>
          <population>Per protocol (excludes one participant that did not receive intravenous ceftriaxone intervention)</population>
          <units>μg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1139.3" spread="200.30"/>
                    <measurement group_id="O2" value="1115.6" spread="180.55"/>
                    <measurement group_id="O3" value="1065.3" spread="176.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence = 90% confidence interval of least squares mean (LSM) within 80%-125%</non_inferiority_desc>
            <param_type>LSM ratio (%; ln-transformed)</param_type>
            <param_value>101.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.95</ci_lower_limit>
            <ci_upper_limit>105.12</ci_upper_limit>
            <estimate_desc>HYLENEX SC/Placebo SC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence = 90% confidence interval of least squares mean (LSM) within 80%-125%</non_inferiority_desc>
            <param_type>LSM ratio (%; ln-transformed)</param_type>
            <param_value>106.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>103.61</ci_lower_limit>
            <ci_upper_limit>110.07</ci_upper_limit>
            <estimate_desc>HYLENEX SC/Intravenous</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence = 90% confidence interval of least squares mean (LSM) within 80%-125%</non_inferiority_desc>
            <param_type>LSM ratio (%; ln-transformed)</param_type>
            <param_value>104.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.59</ci_lower_limit>
            <ci_upper_limit>107.92</ci_upper_limit>
            <estimate_desc>Placebo SC/Intravenous</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf</title>
        <description>Area under the drug concentration-time curve from time zero to infinity, calculated as AUC0-t + Ct/kel (Ct = time of last measurable concentration; kel = terminal elimination rate constant)</description>
        <time_frame>from the start of ceftriaxone administration to infinity</time_frame>
        <population>Per protocol (excludes one participant that did not receive intravenous ceftriaxone intervention)</population>
        <group_list>
          <group group_id="O1">
            <title>HYLENEX SC</title>
            <description>All per-protocol participants administered subcutaneous HYLENEX and ceftriaxone</description>
          </group>
          <group group_id="O2">
            <title>Placebo SC</title>
            <description>All per-protocol participants administered subcutaneous placebo and ceftriaxone</description>
          </group>
          <group group_id="O3">
            <title>Intravenous</title>
            <description>All per-protocol participants administered intravenous ceftriaxone</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf</title>
          <description>Area under the drug concentration-time curve from time zero to infinity, calculated as AUC0-t + Ct/kel (Ct = time of last measurable concentration; kel = terminal elimination rate constant)</description>
          <population>Per protocol (excludes one participant that did not receive intravenous ceftriaxone intervention)</population>
          <units>µg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1162.6" spread="210.36"/>
                    <measurement group_id="O2" value="1141.3" spread="192.86"/>
                    <measurement group_id="O3" value="1085.8" spread="187.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence = 95% confidence interval of least squares mean (LSM) within 80%-125%</non_inferiority_desc>
            <param_type>LSM ratio (%; ln-transformed)</param_type>
            <param_value>101.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.64</ci_lower_limit>
            <ci_upper_limit>104.98</ci_upper_limit>
            <estimate_desc>HYLENEX SC/Placebo SC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence = 90% confidence interval of least squares mean (LSM) within 80%-125%</non_inferiority_desc>
            <param_type>LSM ratio (%; ln-transformed)</param_type>
            <param_value>106.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>103.67</ci_lower_limit>
            <ci_upper_limit>110.33</ci_upper_limit>
            <estimate_desc>HYLENEX SC/Intravenous</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence = 90% confidence interval of least squares mean (LSM) within 80%-125%</non_inferiority_desc>
            <param_type>LSM ratio (%; ln-transformed)</param_type>
            <param_value>105.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.87</ci_lower_limit>
            <ci_upper_limit>108.42</ci_upper_limit>
            <estimate_desc>Placebo SC/Intravenous</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from time of start of intervention administration through 7 days after intervention administered</time_frame>
      <desc>Infusion site reaction assessments performed at baseline (shortly before study drug administration) and at 5, 30 and 45 minutes, and 1, 4, 6, 24, 36 and 48 hours after completion of study drug administration. Other adverse events were to be recorded whenever reported by the participant or observed by study staff.</desc>
      <group_list>
        <group group_id="E1">
          <title>HYLENEX SC</title>
          <description>All participants administered subcutaneous HYLENEX and ceftriaxone</description>
        </group>
        <group group_id="E2">
          <title>Placebo SC</title>
          <description>All participants administered subcutaneous placebo and ceftriaxone</description>
        </group>
        <group group_id="E3">
          <title>Intravenous</title>
          <description>All participants administered intravenous ceftriaxone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infusion site bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infusion site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infusion site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infusion site reaction</sub_title>
                <description>Reported term = &quot;muscle twitching&quot;</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Refers to site of placement of catheter for PK plasma sample collection, not study drug administration site</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For this study, Baxter requires a review of any planned PI results communications (eg, for confidential information) up to 90 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (eg, to allow for intellectual property protection).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George Harb, MD, MPH</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>george_harb@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

